By Adria Calatayud

 

Shares in 4D pharma PLC rose Monday after the company said it has entered into a clinical-trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc. for an oncology treatment.

Under the collaboration, the U.K. pharmaceutical company said it will start a clinical trial this year to evaluate BAVENCIO, a maintenance treatment for urothelial carcinoma co-developed by Merck and Pfizer, in combination with 4D pharma's MRx0518, a biotherapeutic product in development for the treatment of cancer.

The trial will evaluate the combination of BAVENCIO and MRx0518 as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that hasn't progressed with first-line platinum-containing chemotherapy, 4D pharma said.

Urothelial carcinoma is a common type of bladder cancer.

Shares in 4D pharma at 0803 GMT were up 9.1% at 144 pence.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

February 08, 2021 03:26 ET (08:26 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.